Information Provided By:
Fly News Breaks for May 13, 2015
VRTX
May 13, 2015 | 07:19 EDT
After an FDA committee recommended approval of Vortex's Orkambi drug, JMP Securities expects the drug to be approved and continues to anticipate that it will be priced at about $300,000 per year, above current expectations. JMP Securities reiterates a $152 price target and Outperform rating on the shares.
News For VRTX From the Last 2 Days
There are no results for your query VRTX